相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
April W. Armstrong et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2023)
New Topical Therapies for Psoriasis
Ana Maria Le et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)
TYK2 inhibition: changing the treatment landscape for psoriasis?
Abrahim Abduelmula et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2022)
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
Ian M. Catlett et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
Anjaneya Chimalakonda et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2022)
TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
Christine E. Jo et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Diamant Thaci et al.
DERMATOLOGY AND THERAPY (2022)
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System
Ziwei Dong et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN MODERATE TO SEVERE PLAQUE PSORIASIS: 52-WEEK EFFICACY RESULTS FROM THE PHASE 3 POETYK PSO-1 AND POETYK PSO-2 TRIALS
R. B. Warren et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
34660 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: Achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials
Mark Lebwohl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Anjaneya Chimalakonda et al.
DERMATOLOGY AND THERAPY (2021)
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Miguel Nogueira et al.
DRUGS (2020)
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review
April W. Armstrong et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
Sascha Gerdes et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
Robert Harrington et al.
JOURNAL OF INFLAMMATION RESEARCH (2020)
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B. Gordon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Stephen T. Wrobleski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018)
Xingrui He et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Jason E. Hawkes et al.
JOURNAL OF IMMUNOLOGY (2018)
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
Kim Papp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Psoriasis pathogenesis and the development of novel targeted immune therapies
Jason E. Hawkes et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Herpes zoster in psoriasis patients treated with tofacitinib
Kevin L. Winthrop et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Richard B. Warren et al.
LANCET (2017)
CEREBLON MODULATOR CC-220 DECREASES NAIVE AND MEMORY B CELLS AND PLASMACYTOID DENDRITIC CELLS IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS: EXPOSURE-RESPONSE RESULTS FROM A PHASE 2A PROOF OF CONCEPT STUDY
A. Gaudy et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study
G. Palareti et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2016)
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
Calliope A. Dendrou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection
Davide Eletto et al.
NATURE COMMUNICATIONS (2016)
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Small Molecules in the Treatment of Psoriasis
Tiago Torres et al.
DRUG DEVELOPMENT RESEARCH (2015)
Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
John S. Tokarski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
Alexandra Y. Kreins et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study
S. Dogra et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
Sung O. Park et al.
PLOS ONE (2013)
Genetics of Psoriasis: Evidence for Epistatic Interaction between Skin Barrier Abnormalities and Immune Deviation
Judith G. M. Bergboer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome
Sara S. Kilic et al.
JOURNAL OF PEDIATRICS (2012)
Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003-2011
April W. Armstrong et al.
PLOS ONE (2012)
Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference
David M. Rosmarin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2010)
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
Amy Strange et al.
NATURE GENETICS (2010)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
JAK3: A two-faced player in hematological disorders
Melanie G. Cornejo et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
分享论文
